HC Wainwright Has Positive Forecast for ATXS FY2024 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Investment analysts at HC Wainwright increased their FY2024 EPS estimates for Astria Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of ($1.74) for the year, up from their previous estimate of ($1.82). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

ATXS has been the subject of a number of other reports. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen began coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Performance

NASDAQ:ATXS opened at $9.37 on Monday. The firm has a 50-day simple moving average of $11.40 and a two-hundred day simple moving average of $10.62. The firm has a market cap of $528.79 million, a P/E ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Astria Therapeutics by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the period. Tidal Investments LLC bought a new stake in Astria Therapeutics during the 1st quarter valued at approximately $1,664,000. Sofinnova Investments Inc. purchased a new position in Astria Therapeutics in the 2nd quarter worth approximately $552,000. ClariVest Asset Management LLC bought a new position in Astria Therapeutics in the 2nd quarter worth approximately $731,000. Finally, Ameritas Investment Partners Inc. grew its holdings in Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.